|
Patent landscape, scope, and claims: |
US Patent 6,030,643: What the Claims Actually Cover and Where the Landscape Tightens
US 6,030,643 claims specific solid-dose formulations of oxaprozin salts (potassium, sodium, or Tris) with defined excipient constraints and dissolution performance in a set in vitro test. The patent also claims pain and inflammation treatment methods tied to those same dissolution and composition properties. The actionable scope is narrow in chemistry (oxaprozin salts only) but moderately broad in formulation execution (multiple salt options and excipient substitutions), with key “design-around” pressure points: magnesium stearate and metallic stearates, methylcellulose limits, and dissolution thresholds (75% in 30 minutes; dependent claim adds 95%).
What are the independent claim anchors?
What does claim 1 cover?
Claim 1 is the core “composition + dissolution + excipient-limit” anchor.
Claim 1: composition
- Solid dosage form
- Active agent: potassium, sodium, or Tris salt of oxaprozin
- Magnesium stearate limit: < 1% (w/w)
- Dissolution performance: about 75% of active becomes dissolved in:
- 1000 mL
- pH 7.4 phosphate buffer
- 37°C
- paddle stirring at 75 rpm
- within about 30 minutes
Business meaning for scope
- The patent is not on “oxaprozin itself” but on oxaprozin salts in a solid dosage form meeting a specific dissolution profile under specific apparatus conditions.
- The <1% magnesium stearate condition becomes a gating limitation even if dissolution is met.
What does claim 9 expand to?
Claim 9 adds a second formulation axis: a lubricant selection concept.
Claim 9: composition
- Solid dosage form
- Active agent: potassium, sodium, or Tris oxaprozin salt
- Includes:
- (i) oxaprozin salt
- (ii) a lubricant selected from:
- water-insoluble lubricants, and/or
- water-soluble lubricants
- Dissolution performance: same as claim 1 (about 75% in 30 minutes in pH 7.4 buffer at 37°C with 75 rpm paddle)
Business meaning for scope
- Claim 9 broadens excipient strategy via a lubricant taxonomy.
- It also creates additional infringement hooks when a formulation uses a listed lubricant type plus the dissolution profile.
What does claim 23 lock down more tightly?
Claim 23 gives a “percent ranges” scaffold and adds specific excipient choices.
Claim 23: composition
- Solid dosage form with:
- (i) potassium/sodium/Tris oxaprozin salt: 70% to 90% by weight
- (ii) stearic acid: 1% to 4%
- (iii) pregelatinized corn starch: 0.25% to 25%
- (iv) microcrystalline cellulose optionally: 0% to 27%
- Dissolution performance: same as claim 1 (about 75% in 1000 mL pH 7.4 phosphate buffer at 37°C, paddle 75 rpm, about 30 minutes)
Business meaning for scope
- Claim 23 is narrower than claim 1 because it is composition-range limited.
- It is also more useful for enforcement because it maps directly onto a typical high-active-content tablet process.
Dependent claims that materially change infringement risk
What excipient constraints do the dependents create?
The independent claims are already tied to dissolution and magnesium stearate. Dependents further constrain excipient classes.
| Dependent claim |
Limitation introduced |
Practical enforcement consequence |
| Claim 6 |
< 2% (w/w) methylcellulose |
High-risk if methylcellulose used above threshold |
| Claim 7 |
“substantially free of metallic stearates” |
A “catch” for stearate salts beyond magnesium stearate |
| Claim 12 |
< 1% (w/w) magnesium stearate (on claim 9/9-family) |
Reinforces low-magnesium constraint |
| Claim 13 |
“substantially free of metallic stearates” (on claim 9-family) |
Reinforces metallic stearate avoidance |
| Claim 14 |
< 2% methylcellulose (on claim 9-family) |
Reinforces methylcellulose avoidance |
| Claim 26 |
< 1% magnesium stearate (on claim 23-family) |
Reinforces low-magnesium constraint |
| Claim 27 |
“substantially free of metallic stearates” (on claim 23-family) |
Reinforces metallic stearate avoidance |
| Claim 28 |
< 2% methylcellulose (on claim 23-family) |
Reinforces methylcellulose avoidance |
Key take
- The “substantially free of metallic stearates” language functions like a broader prohibition than the numeric magnesium stearate limit.
- A formulation can technically keep magnesium stearate <1% and still fall under “metallic stearates” depending on what excipients are counted as metallic stearates.
How broad are the salt and dose form elements?
- Salt: potassium, sodium, or Tris oxaprozin are all covered.
- Dosage form: tablets, pills, caplets are explicitly called out (claims 8 and 31, and dependent language tied to those).
What lubricant choices are explicitly named?
Claim 16 and claim 17 create explicit “lubricant list” options under claim 9.
| Claim |
Lubricant type |
Examples (as listed) |
| Claim 16 |
water-insoluble lubricants |
calcium stearate, zinc stearate, stearic acid, hydrogenated vegetable oil, talc |
| Claim 17 |
water-soluble lubricants |
sodium lauryl sulfate, sodium stearyl fumarate |
Key take
- Stearic acid is simultaneously:
- allowed in the claim 23 excipient ranges (1% to 4%), and
- listed among water-insoluble lubricants (claim 16).
- That makes stearic acid a “safe harbor” within the patent’s own taxonomy, not an avoided excipient.
Dissolution thresholds: the performance hook that converts formulation into infringement
What is the core dissolution threshold?
Across composition and method claims, the same test scaffold recurs:
- Buffer: pH 7.4 phosphate buffer
- Volume: 1000 mL
- Temperature: 37°C
- Apparatus: paddle stirring
- Speed: 75 rpm
- Time: about 30 minutes
- Performance: about 75% dissolved (independent claims 1, 9, 23; method claims 29, 32; dependent 35, 36 adds 95%)
Where do claims ratchet up?
- Claim 35: composition (claims 1, 9, or 23 family) where about 95% dissolves within about 30 minutes.
- Claim 36: method where about 95% dissolves within about 30 minutes.
Key take
- The patent has two performance tiers:
- “about 75%” (primary)
- “about 95%” (higher-performance dependent)
- A product that clears 75% but not 95% still maps to the primary tier; a product that clears both maps to the higher tier.
What do the method claims require, beyond treating pain/inflammation?
How do claims 29 and 32 work?
The method claims require:
- administering an effective amount
- of a pharmaceutical composition in a solid dosage form comprising the oxaprozin salts
- and meeting the same dissolution performance conditions (about 75% dissolved in 1000 mL pH 7.4 phosphate buffer at 37°C with paddle 75 rpm within about 30 minutes)
- for pain (claim 29) and inflammation/inflammation-associated disorders (claim 32)
Actionable scope
- The medical indication is “pain” and “inflammation/inflammation-associated disorders.”
- The infringement hook is not just therapeutic effect; it is the dissolution-qualified composition.
What do dependent method claims add?
- Claim 30 ties active agent amount to 37.14% to 100% by weight (method claim 29 dependency).
- Claim 31 limits dosage form to tablet/pill/caplet.
- Claim 33 ties active amount for claim 32 to 37.14% to 100%.
- Claim 34 repeats dosage form limitation for claim 32.
- Claim 36 raises dissolution from about 75% to about 95% within about 30 minutes.
Composition design map: which elements are most likely to be contested?
1) Dissolution in a specific apparatus setup
The claims require a test outcome tied to:
- pH 7.4
- 1000 mL
- paddle 75 rpm at 37°C
- about 30 minutes
If a challenger can show a product’s dissolution profile does not meet “about 75%” under those exact conditions (or argue the “about” qualifier), infringement weakens.
2) Magnesium stearate and metallic stearates
The claims create numeric and qualitative constraints:
- magnesium stearate: <1% (w/w) (claims 1, 12, 26)
- “substantially free of metallic stearates” (claims 7, 13, 27)
This pair matters because typical tablet lubricants and flow aids often include stearates. The patent is positioned to penalize stearate-heavy lubrication strategies.
3) Methylcellulose cap
- methylcellulose: <2% (w/w) (claims 6, 14, 28)
4) Oxaprozin salt identity
Only potassium, sodium, or Tris salts are covered. That means:
- other salt forms (if used) fall outside the claim wording.
Claim-by-claim landscape interpretation for freedom-to-operate (FTO)
Where the patent is narrow
- Only oxaprozin salts (potassium/sodium/Tris) are included as actives.
- Solid dosage forms are required; not a suspension, not a gel.
- The dissolution profile is tied to a standardized in vitro method (not a general “rapid dissolution” descriptor).
Where the patent is broader than it first appears
- Multiple salt forms are covered.
- Multiple dosage forms are covered (tablet/pill/caplet).
- Lubricant selection is broadened under claim 9 via water-insoluble and water-soluble categories, and includes multiple example chemicals.
“Design-around” pressure points (practical, claim-driven)
The patent’s own claim architecture concentrates risk on a few levers:
- Keep stearate burden below claim thresholds
- Avoid formulations with magnesium stearate above 1% and maintain “substantially free” of metallic stearates.
- Avoid methylcellulose above 2%
- Stay below the methylcellulose cap if methylcellulose is used at all.
- Target dissolution strategy that misses “about 75% in 30 minutes”
- A product can remain fully within acceptable therapeutic performance while missing the exact dissolution threshold in the exact test parameters.
- If pursuing excipient systems involving stearic acid
- Stearic acid is permitted and explicitly contemplated within claim 23 ranges and claim 16 lubricant list. It is not a safe avoidance target.
Key Takeaways
- US 6,030,643 claims oxaprozin potassium, sodium, or Tris salts in solid dosage forms with a required dissolution outcome: about 75% dissolved in 1000 mL pH 7.4 phosphate buffer at 37°C with paddle 75 rpm within about 30 minutes.
- The strongest formulation liability drivers are excipient limits: <1% magnesium stearate, substantially free of metallic stearates, and <2% methylcellulose.
- Claim 23 adds a high-specificity composition range (oxaprozin salts 70% to 90%, stearic acid 1% to 4%, pregelatinized corn starch 0.25% to 25%, microcrystalline cellulose optional 0% to 27%) while keeping the same dissolution requirement.
- Method claims for pain and inflammation are tied to administration of the same dissolution-qualified composition, so formulation non-infringement can defeat method coverage as well.
- Dependent claims create a higher-performance tier: about 95% dissolved within about 30 minutes (claims 35 and 36).
FAQs
-
Does the patent cover oxaprozin free acid?
No. The active agent language requires potassium, sodium, or Tris salt of oxaprozin.
-
Is a generic tablet covered if it has the same active but different excipients?
It depends on whether it meets the dissolution threshold and the stearate/methylcellulose limits stated in the claims.
-
If magnesium stearate is under 1%, can “metallic stearates” still create infringement risk?
Yes. Claims also require the composition to be “substantially free of metallic stearates,” which can capture other stearate-type metallic excipients.
-
Do the method claims require a specific medical indication wording only?
They require treatment of pain (claim 29) or inflammation/inflammation-associated disorders (claim 32) by administering a dissolution-qualified solid-dose composition as defined.
-
What is the maximum dissolution performance requirement in dependent claims?
Dependent claims 35 and 36 add “about 95%” dissolved within about 30 minutes in the same dissolution test framework.
References
[1] US Patent 6,030,643.
More… ↓
⤷ Start Trial
|
